by In2Pharma | Nov 4, 2019 | News
Europe EMA’s human medicines committee (CHMP) is requesting as a matter of precaution that marketing authorization holders (MAHs) for human medicines containing chemically synthesized active substances review their medicines for the possible presence of nitrosamines...
